O'Kane Dermot B, Dave Sameer K, Gore Neel, Patel Farhaan, Hoffmann Tammy C, Trill Jeanne L, Del Mar Chris B
Centre for Research in Evidence-Based Practice (CREBP), Bond University, Gold Coast, QLD, Australia.
Cochrane Database Syst Rev. 2016 Apr 19;4(4):CD010745. doi: 10.1002/14651858.CD010745.pub2.
Uncomplicated urinary tract infection (UTI) is the most common bacterial infection in women, characterised by dysuria and urinary frequency. Urinary alkalisers are widely used in some countries for the symptomatic treatment of uncomplicated UTI, and they are recommended in some national formularies. However, there is a lack of empirical evidence to support their use for UTI and some healthcare guidelines advise against their use.
We aimed to look at the benefits and harms of the use of urinary alkalisers for the treatment of uncomplicated UTIs in adult women.
We searched the Cochrane Kidney and Transplant Specialised Register to 19 January 2016 through contact with the Trials Search Co-ordinator using search terms relevant to this review.
All randomised controlled trials (RCTs) and quasi-RCTs on the use of (any) urinary alkalisers (either exclusively or non-exclusively) for the symptomatic treatment of uncomplicated UTI amongst women aged 16 and over, were included. Studies were eligible if they included patients whose diagnosis of UTI was decided by symptoms alone, or positive urine dipstick test or urine culture; and patients with recurrent UTI, provided patients had no symptoms of UTI in the two weeks prior to the onset of symptoms that lead them to seek medical advice. Studies were ineligible if they studied patients with complicated UTIs; immune-compromising conditions; acute pyelonephritis; or chronic conditions such as interstitial cystitis.
Three authors independently assessed and screened papers, and this was repeated by two separate authors (independently). An additional investigator acted as arbitrator, where necessary. There were no papers which fulfilled the inclusion criteria for this review, and therefore no data extraction was performed.
Our search identified 172 potential studies for inclusion. However, following assessment none fulfilled the inclusion criteria for this review.
AUTHORS' CONCLUSIONS: Until relevant evidence is generated from randomised trials, the safety and efficacy of urinary alkalisers for the symptomatic treatment of uncomplicated UTI remains unknown.
单纯性尿路感染（UTI）是女性中最常见的细菌感染，其特征为尿痛和尿频。尿路碱化剂在一些国家被广泛用于单纯性UTI的对症治疗，并且在一些国家药典中也有推荐。然而，缺乏支持其用于UTI治疗的经验证据，一些医疗保健指南不建议使用。
我们旨在研究使用尿路碱化剂治疗成年女性单纯性UTI的益处和危害。
我们通过与试验检索协调员联系，使用与本综述相关的检索词，检索截至2016年1月19日的Cochrane肾脏和移植专业注册库。
纳入所有关于使用（任何）尿路碱化剂（单独或非单独使用）对16岁及以上女性单纯性UTI进行对症治疗的随机对照试验（RCT）和半随机对照试验。如果研究包括仅通过症状、尿试纸阳性试验或尿培养确诊UTI的患者；以及复发性UTI患者，前提是患者在导致其寻求医疗建议的症状发作前两周内没有UTI症状，则这些研究符合条件。如果研究的是复杂性UTI患者；免疫功能低下情况；急性肾盂肾炎；或慢性疾病如间质性膀胱炎，则这些研究不符合条件。
三位作者独立评估和筛选论文，另外两位作者（独立地）重复此过程。必要时，另一名研究人员担任仲裁员。没有论文符合本综述的纳入标准，因此未进行数据提取。
我们的检索确定了172项可能纳入的研究。然而，经过评估，没有一项符合本综述的纳入标准。
在随机试验产生相关证据之前，尿路碱化剂用于单纯性UTI对症治疗的安全性和有效性仍然未知。
